05.20.20

FDA Gives Octapharma USA Green Light to Conduct Phase 3 Clinical Trial of COVID-19 Treatment

Source: Octapharma USA

The FDA  has approved the investigational new drug application submitted by Octapharma USA for a phase three clinical trial on the efficacy and safety of Octagam 10% [Immune Globulin Intravenous (Human)] therapy in COVID-19 patients with severe disease progression.

The primary objective of the randomized, double-blind, placebo-controlled, multicenter study is to determine if high-dose Octagam 10% therapy will slow or stop respiratory deterioration in patients with severe coronavirus disease. The secondary objectives of the study are to measure the effects of a high-dose of Octagam 10% on slowing or stopping the clinical progression of COVID-19 by improving pulmonary function, quality of life, and correlated impact on metabolic factors.
 
“Although many therapies based on provisional data have been proposed for patients who suffer from COVID-19, known treatments are limited,” Octapharma USA President Flemming Nielsen said in a company news release. “Intravenous immunoglobulin (IVIG), which consists of pooled IgG preparations from thousands of donors, has been used to treat patients with immune-mediated diseases for almost 40 years. Our hypothesis is that the use of IVIG in the prophylaxis of severe infections, especially in immunocompromised patients, makes it an attractive therapeutic possibility for COVID-19.”
 
The study will begin immediately at approximately 10 U.S. research sites with the goal of enrolling about 54 adult patients diagnosed with COVID-19 with a resting SpO2 of ≤93%, requiring oxygen supplementation. SpO2, also known as oxygen saturation, is a measure of the amount of oxygen-carrying hemoglobin in the blood relative to the amount of hemoglobin not carrying oxygen.

Patients in the trial will be randomized to receive either Octagam 10% or a placebo, and will be monitored for approximately 33 days. Those receiving Octagam 10% will be administered a total dose of 2 g/kg as an intravenous infusion of 0.5 g/kg over a 2-hour period daily for 4 consecutive days. Octapharma hopes to report study results by the third quarter of 2020.
 
“Several case reports on utilizing IVIG treatment for COVID-19 patients have shown  positive results,” Wolfgang Frenzel, MD, Head of Research & Development at Octapharma, said in the news release. “The effects of the immune-modulating properties of IVIG in severely-ill COVID-19 patients appeared to be demonstrated in the case reports and we are, therefore, hopeful that we will observe improved clinical status in the patients receiving Octagam 10%.”
 

Related Content